This article is more than 5 years old. Information may no longer be current.

RPS partners with Allergan, expands dry eye efforts

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Rapid Pathogen Screening Inc. announced its copromotional partnership with Allergan to improve care for dry eye disease through its InflammaDry in-office test.

RPS also reported in a press release that to meet demand for InflammaDry, the company has established an eye care sales and marketing team to head the global commercial efforts.

InflammaDry is a single-use test that requires no additional equipment to administer or interpret results. The InflammaDry process takes less than 2 minutes to complete and detects MMP-9, an inflammatory marker consistently elevated in the tears of patients with dry eye disease, according to the press release.

“RPS is emboldened by the positive response following the U.S. clearance of InflammaDry,” RPS CEO, President and Chairman Robert Sambursky, MD, said in the release. “Expanding RPS’s commercial organization, including a copromotional partnership with Allergan, a global leader in eye care, will help to facilitate improved care for the millions of patients who suffer from dry eye disease.”

InflammaDry is CE-marked, 510(k) cleared, CLIA-waived, and commercially available in Europe, the U.S., Canada and other countries worldwide, said the press release.